The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.
 
Jad Chahoud
Consulting or Advisory Role - AVEO; DAVA Pharmaceuticals; Eisai; Exelixis; Merck; Pfizer
 
Yousef Zakharia
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Cardinal Health; Castle Biosciences; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genzyme; Gilead Sciences; Janssen; Myovant Sciences; Novartis; Pfizer; Roche/Genentech; Seagen; TTC Oncology
Research Funding - Eisai (Inst); Exelixis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Newlink Genetics
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Sanjay Goel
Stock and Other Ownership Interests - Johnson and Johnson; Merck; Moderna Therapeutics
Honoraria - GlaxoSmithKline
Research Funding - Amgen (Inst); BioMed Valley Discoveries (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Takeda (Inst); Xilio Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364
 
Bartosz Chmielowski
Consulting or Advisory Role - Atreca; Delcath Systems; Instil Bio; Novartis; Regeneron; Replimune; SpringWorks Therapeutics; Treeline Biosciences
Research Funding - Adagene (Inst); Advenchen Laboratories (Inst); Ascentage Pharma (Inst); AskGene Pharma (Inst); Atreca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Infinity Pharmaceuticals (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); Macrogenics (Inst); PTC Therapeutics (Inst); RAPT Therapeutics (Inst); Replimune (Inst); TriSalus Life Sciences (Inst); Xencor (Inst); Xilio Therapeutics (Inst)
Travel, Accommodations, Expenses - Instil Bio
 
Diana L. Hanna
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
Research Funding - Agenus (Inst); Dragonfly Therapeutics (Inst); Indaptus Therapeutics (Inst); Toray Industries (Inst); Xilio Therapeutics (Inst)
 
Gregory A. Daniels
No Relationships to Disclose
 
Richard Cheng Han Wu
Consulting or Advisory Role - Tempus
Research Funding - Iovance Biotherapeutics (Inst); Regeneron (Inst); Xilio Therapeutics (Inst)
 
Suthee Rapisuwon
Stock and Other Ownership Interests - Cardiff Oncology
Honoraria - General Dynamics Information Technology (GDIT)
Consulting or Advisory Role - Castle Biosciences; Replimune
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Randolph Hurley
No Relationships to Disclose
 
Anurag Gupta
Employment - Samyang Biopharm USA; Xilio Therapeutics
Stock and Other Ownership Interests - Thermo Fisher Scientific (I); Xilio Therapeutics
 
Meghan Duncan
No Relationships to Disclose
 
Aigerim Siu
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Ekta Patel
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - MustangBio; Xilio Therapeutics
Patents, Royalties, Other Intellectual Property - Patents, TCR2, Mustang Bio
 
Damiano Fantini
Employment - Merck (I); Xilio Therapeutics
Stock and Other Ownership Interests - Lilly; Merck (I); Xilio Therapeutics
 
David Crowe
Employment - Xilio Therapeutics
 
Sattanathan Paramasivan
Employment - Selecta Biosciences; Xilio Therapeutics
Stock and Other Ownership Interests - ADMA Biologics; Allogene Therapeutics; Amylyx; AstraZeneca; Aurinia Pharmaceuticals; Avadel Pharmaceuticals; Avidity Biosciences; Baudax Bio; Biomarin; BridgeBio Pharma; Bristol Myers Squibb Foundation; Deciphera; Dicerna; Gritstone Bio; Iovance Biotherapeutics; Merck; Ocugen; PepGen; Pfizer; Roche; Sandoz; Selecta Biosciences; Takeda; VERA THERAPEUTICS; Xilio Therapeutics
 
Katarina Luptakova
Employment - Xilio Therapeutics
Stock and Other Ownership Interests - Xilio Therapeutics
 
Howard L. Kaufman
Employment - Ankyra Therapeutics
Leadership - Ankyra Therapeutics
Stock and Other Ownership Interests - Immuneering; Replimune
Honoraria - Society for Immunotherapy of Cancer
Consulting or Advisory Role - Castle Biosciences; Marengo Therapeutics; Midatech Pharma; Tatum Bioscience; Virogin Biotech
 
Diwakar Davar
Honoraria - ACM Biolabs; Clinical Care Options (CCO); Gerson Lehrman Group; Medical Learning Group; Merck; Xilio Therapeutics
Consulting or Advisory Role - ACM Bio; Ascendis Pharma; Clinical Care Options; Gerson Lehrman Group; Replimune; TriSalus Life Sciences; Xilio Therapeutics
Speakers' Bureau - Castle Biosciences
Research Funding - Arcus Biosciences; CellSight Technologies; Checkmate Pharmaceuticals; GlaxoSmithKline; Merck; Merck; Zucero Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Application No.: 63/124,231; Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy